The duration of adjuvant tamoxifen therapy.
Bilimoria
M M
MM
Department of Surgery, Northwestern University Medical School, Chicago, IL 60611, USA.
Jordan
V C
VC
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D002318:Cardiovascular Diseases / Q000517:prevention & control; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000139:chemically induced; D004965:Estrogen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004967:Estrogens; D005260:Female; D006801:Humans; D008593:Menopause; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009376:Neoplasms, Hormone-Dependent / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016019:Survival Analysis; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens; D013629:Tamoxifen